不同方案药物治疗泌尿系统感染的经济学探析
|
摘要
目的对不同药物治疗方案在泌尿系统感染治疗中的经济学价值进行评价分析。方法抽取我院收治的泌尿系统感染患者168例,将其按照治疗方法分成甲、乙、丙三组,甲组患者采取左氧氟沙星片联合通淋颗粒进行治疗,乙组患者采取单纯左氧氟沙星片进行治疗,丙组患者采取头孢特仑新戊酯片进行治疗,对比三组患者的临床疗效和经济成本。结果甲乙丙三种方案的成本-效果比值以丙组最高(P<0.05),甲组最低(P<0.05)。结论甲组治疗方案采取中西医结合方式进行治疗,疗效显著,经济成本较低,为治疗最佳方案,值得关注。
Objective Values for different drug treatment programs in economics in the treatment of urinary tract infections were evaluated in the analysis.Methods 168 patients of urinary system in our hospital were setected,will be divided into three groups according to treatment B,C,Group A patients taking levofloxacin tablets tonglin particles combined treatment group B patients taking levofloxacin alone treatment,patients in Group C Cefteram take amyl acetate tablets for treatment,comparing the clinical efficacy and economic costs of the three groups of patients.Results Of the three components of ABC programs-the effect of the highest ratios in group C(P<0.05),Group A lowest(P<0.05). Conclusion Division regimen Integrative approach taken for treatment,a significant effect,lower economic cost,the best solution for the treatment worthy of attention.
Objective Values for different drug treatment programs in economics in the treatment of urinary tract infections were evaluated in the analysis.Methods 168 patients of urinary system in our hospital were setected,will be divided into three groups according to treatment B,C,Group A patients taking levofloxacin tablets tonglin particles combined treatment group B patients taking levofloxacin alone treatment,patients in Group C Cefteram take amyl acetate tablets for treatment,comparing the clinical efficacy and economic costs of the three groups of patients.Results Of the three components of ABC programs-the effect of the highest ratios in group C(P<0.05),Group A lowest(P<0.05). Conclusion Division regimen Integrative approach taken for treatment,a significant effect,lower economic cost,the best solution for the treatment worthy of attention.
引文
[1]刘兆兰,孙瑛,等.药物有效性和安全性的卫生经济学评[J].中国药物警戒,2010,7(7):403-406.
[2]杨启文,徐英春,谢秀丽,等.全国10所医院院内与社区感染常见病原菌耐药性分析[J].中华医院感染学杂志,2009,19(9):1133-1138.
[3]李影雄,郑宝林,劳思聪,等.通淋颗粒加诺氟沙星治疗急性尿路感染的疗效观察[J].国际医药卫生导报,2009,15(15):78-79.
[4]《中国药物经济学评价指南》课题组,刘国恩,胡善联,等.中国药物经济学评价指南(2011版)[J].中国药物经济学,2011,12(3):102-103.
[5]宗欣,孙利华.药物经济学评价方法及其评价标准[J].中国药物经济学,2011,12(3):214-215.
[6]何金鸿.加替沙星与左氧氟沙星治疗泌尿系统感染的临床疗效及经济学分析[J].医学信息(上旬刊),2011,17(8):343-345.
[7]冀建明,杨常成,王保平.左氧氟沙星序贯疗法治疗泌尿系统感染的成本-效果分析[J].中国药业,2009,6(19):218-219.
[8]王惠玲,赵奎,李学朝.司帕沙星与加替沙星治疗泌尿系统感染的成本-效果分析[J].当代医学,2009,7(30):115-116.
[9]熊一岚,万力生.3种方案治疗儿童原发性遗尿症的药物经济学分析[J].中国医院用药评价与分析,2010,11(3):254-255.
[10]郑海珍.莫西沙星与左氧氟沙星治疗泌尿道感染的疗效及成本-效果分析[J].中国药业,2010,13(7):162-163.
[2]杨启文,徐英春,谢秀丽,等.全国10所医院院内与社区感染常见病原菌耐药性分析[J].中华医院感染学杂志,2009,19(9):1133-1138.
[3]李影雄,郑宝林,劳思聪,等.通淋颗粒加诺氟沙星治疗急性尿路感染的疗效观察[J].国际医药卫生导报,2009,15(15):78-79.
[4]《中国药物经济学评价指南》课题组,刘国恩,胡善联,等.中国药物经济学评价指南(2011版)[J].中国药物经济学,2011,12(3):102-103.
[5]宗欣,孙利华.药物经济学评价方法及其评价标准[J].中国药物经济学,2011,12(3):214-215.
[6]何金鸿.加替沙星与左氧氟沙星治疗泌尿系统感染的临床疗效及经济学分析[J].医学信息(上旬刊),2011,17(8):343-345.
[7]冀建明,杨常成,王保平.左氧氟沙星序贯疗法治疗泌尿系统感染的成本-效果分析[J].中国药业,2009,6(19):218-219.
[8]王惠玲,赵奎,李学朝.司帕沙星与加替沙星治疗泌尿系统感染的成本-效果分析[J].当代医学,2009,7(30):115-116.
[9]熊一岚,万力生.3种方案治疗儿童原发性遗尿症的药物经济学分析[J].中国医院用药评价与分析,2010,11(3):254-255.
[10]郑海珍.莫西沙星与左氧氟沙星治疗泌尿道感染的疗效及成本-效果分析[J].中国药业,2010,13(7):162-163.